- Company
- Korean-made IMD Rosuzet and Zemimet prevail over COVID-19
- by An, Kyung-Jin Jul 17, 2020 05:55am
- Apparently a number of incrementally modified drugs (IMDs) developed with Korean-made technology excelled in the prescription drug market amid novel coronavirus (COVID-19) pandemic. A dyslipidemia combination drug Rosuzet and an antidiabetic combination drug Zemiglo recorded two-digit growth and settled on the top chart in the prescrip
- Company
- 2nd single-agent immunotherapy added for NSCLC first-line
- by Eo, Yun-Ho Jul 16, 2020 05:55am
- Another immunotherapy is expected to be added as a first-line treatment option in lung cancer. The pharmaceutical industry sources reported, Roche Korea has recently submitted an application to Korea’s Ministry of Food and Drug Safety (MFDS) to indicate programmed death-ligand 1 (PD-L1) inhibiting immunotherapy Tecentriq (atezolizumab)
- Company
- Influenza vaccine inoculation rate doubled from last year
- by Jul 16, 2020 05:54am
- n the aftermath of COVID-19, the number of influenza vaccination in the National Essential Immunization Vaccine (NIP) increased significantly in the first half of this year. On the other hand, for the same reason, other essential vaccination rates are rather have declined. According to the KCDC on the 13th, the number of NIP inoculations from
- Company
- "Ezetimibe combination drug, now key option in dyslipidemia"
- by Eo, Yun-Ho Jul 15, 2020 06:33am
- Statin has been demonstrating outstanding efficacy in low-density lipoprotein cholesterol (LDL-C) level control, while showing an assuring benefit in risk of cardiovascular death. The medicine has surely shifted the paradigm of dyslipidemia management. Nevertheless, there is no perfect drug in this world. Statin also has concerning repor
- Company
- Zepzelca by Boryung designated as an orphan Drug
- by An, Kyung-Jin Jul 15, 2020 06:33am
- Boryung announced on the 13th that it is in the process of receiving a new drug called small-cell lung cancer (SCLC) 'Zepzelca' (Lurbinectedin) as an orphan drug. Zepzelca is an anticancer drug that Boryung has exclusive rights to domestic development and sales. In 2017, Boryung signed a technology introduction contract with PharmaMar in S
- Company
- Xofluza efficacy confirmed in household transmission
- by Eo, Yun-Ho Jul 14, 2020 06:12am
- A next-generation flu drug Xofluxa’s effect of preventing flu virus transmission among the patient’s household member has been confirmed. The latest edition of New England Journal of Medicine (NEJM) published on July 8 reported the clinical findings of Xofluza (baloxavir marboxil) and its flu preventive effect. The study evaluated
- Company
- 14 new drugs approved from Jan to June with no Korean drug
- by Jul 14, 2020 06:12am
- Korea’s Ministry of Food and Drug Safety (MFDS) reported total 14 new drugs have been approved from Jan 1 to June 30 this year. While none of them were a Korean-made, the absence of Korean-made new drug has continued for two years now. Pfizer Pharmaceutical Korea, Astellas Pharma Korea and Bayer Korea received the highest number of new drug
- Company
- LG Chem launches filler's clinical trial in China
- by An, Kyung-Jin Jul 14, 2020 02:34am
- LG Chem is launching a large-scale clinical trial in China with the new product of Yvoire, a hyaluronic acid filler brand. It is an ambition to secure the differentiation and expand the market share by preparing clinical data of Y-Solution, which was introduced as a premium line. LG Chem recently unveiled a new clinical trial plan for Yvo
- Company
- DongKook & YuYu have challenged Dutasteride &Tadalafil
- by Kim, Jin-Gu Jul 13, 2020 06:13am
- The prostate hyperplasia & erectile dysfunction complex market competition is expected to become even hotter. With only Hanmi's Gugu tams (Tamsulosin + Tadalafil ) released on the market, DongKook and YuYu Pharma have challenged. According to the pharmaceutical industry on the 13th, DongKook recently approved a clinical trial phase III IN
- Company
- Eligibility for HPV vaccine Gardasil9 extends up to age 45 i
- by Eo, Yun-Ho Jul 13, 2020 06:12am
- Vaccination eligible age for the human papillomavirus (HPV) vaccine Gardasil9 has been extended up to age 45 in Korea. Pharmaceutical industry sources reported Ministry of Food and Drug Safety (MFDS) has approved MSD expanding the indication to vaccinate in female aged 27 to 45. Unlike the U.S., however, the Korean health authority exclud
